JP2001510683A - Ｐｓｅｕｄｏｍｏｎａｓ体外毒素Ａ様キメラ免疫原 - Google Patents

Ｐｓｅｕｄｏｍｏｎａｓ体外毒素Ａ様キメラ免疫原

Info

Publication number
JP2001510683A
JP2001510683A JP2000502207A JP2000502207A JP2001510683A JP 2001510683 A JP2001510683 A JP 2001510683A JP 2000502207 A JP2000502207 A JP 2000502207A JP 2000502207 A JP2000502207 A JP 2000502207A JP 2001510683 A JP2001510683 A JP 2001510683A
Authority
JP
Japan
Prior art keywords
domain
amino acid
sequence
immunogen
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000502207A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001510683A5 (enExample
Inventor
ジェイ． フィツジェラルド，デイビッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Health and Human Services
Original Assignee
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of Health and Human Services filed Critical United States Department of Health and Human Services
Publication of JP2001510683A publication Critical patent/JP2001510683A/ja
Publication of JP2001510683A5 publication Critical patent/JP2001510683A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2000502207A 1997-07-11 1998-07-10 Ｐｓｅｕｄｏｍｏｎａｓ体外毒素Ａ様キメラ免疫原 Pending JP2001510683A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5237597P 1997-07-11 1997-07-11
US60/052,375 1997-07-11
PCT/US1998/014341 WO1999002713A1 (en) 1997-07-11 1998-07-10 Pseudomonas exotoxin a-like chimeric immunogens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008316284A Division JP2009079068A (ja) 1997-07-11 2008-12-11 Ｐｓｅｕｄｏｍｏｎａｓ体外毒素Ａ様キメラ免疫原

Publications (2)

Publication Number Publication Date
JP2001510683A true JP2001510683A (ja) 2001-08-07
JP2001510683A5 JP2001510683A5 (enExample) 2006-01-05

Family

ID=21977213

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000502207A Pending JP2001510683A (ja) 1997-07-11 1998-07-10 Ｐｓｅｕｄｏｍｏｎａｓ体外毒素Ａ様キメラ免疫原
JP2008316284A Pending JP2009079068A (ja) 1997-07-11 2008-12-11 Ｐｓｅｕｄｏｍｏｎａｓ体外毒素Ａ様キメラ免疫原

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008316284A Pending JP2009079068A (ja) 1997-07-11 2008-12-11 Ｐｓｅｕｄｏｍｏｎａｓ体外毒素Ａ様キメラ免疫原

Country Status (10)

Country Link
US (1) US8092809B2 (enExample)
EP (1) EP1000163B1 (enExample)
JP (2) JP2001510683A (enExample)
AT (1) ATE307208T1 (enExample)
AU (1) AU731703B2 (enExample)
CA (1) CA2295971C (enExample)
DE (1) DE69831951T2 (enExample)
DK (1) DK1000163T3 (enExample)
ES (1) ES2249838T3 (enExample)
WO (1) WO1999002713A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006025782A (ja) * 2004-07-21 2006-02-02 Healthbanks Biotech Co Ltd スーパー抗原融合蛋白及びその応用方法
JP2011510988A (ja) * 2008-01-31 2011-04-07 ヘルスバンクス ユーエスエー インコーポレイテッド ワクチンとしてのキメラｈｉｖ融合タンパク質

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1078988A1 (en) * 1999-08-27 2001-02-28 Academia Sinica Pseudomonas fusion protein vaccines
US6838553B1 (en) * 1999-10-05 2005-01-04 Academia Sinica Peptide repeat immunogens
EP1242122B1 (en) * 1999-10-22 2009-09-30 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Delivery of proteins across polar epithelial cell layers
US7964200B2 (en) 2005-05-18 2011-06-21 Children's Hospital & Research Center At Oakland Methods and compositions for immunizing against Chlamydia infection
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
US8932586B2 (en) 2011-09-06 2015-01-13 Intrexon Corporation Modified forms of Pseudomonas exotoxin A
CN109608550B (zh) * 2012-12-05 2020-09-11 生控基因疫苗股份有限公司 用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白
US9861681B2 (en) 2013-04-18 2018-01-09 The United States of America as represented by the Secretary of the Army, on behalf of the United States Army Medical Research Institute of Infectious Diseases Therapeutic compositions for neutralizing type I interferons, and methods of use
CA2985381C (en) * 2015-06-01 2020-03-24 Reber Genetics Co., Ltd. Vaccine compositions against porcine reproductive and respiratory syndrome and porcine circovirus associated diseases
PL3762009T3 (pl) 2018-03-08 2022-09-12 Applied Molecular Transport Inc. Pochodzące z toksyny konstrukty dostarczające do dostarczania doustnego
SG11202104734YA (en) 2018-11-07 2021-06-29 Applied Molecular Transport Inc Cholix-derived carriers for oral delivery of heterologous payload

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4545985A (en) * 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
US6022950A (en) * 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5668255A (en) * 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
CA1289880C (en) * 1985-12-06 1991-10-01 Jeffrey L. Winkelhake Anti-human ovarian cancer immunotoxins and methods of use thereof
US5082927A (en) * 1986-09-24 1992-01-21 The United States Of America As Represented By The Department Of Health And Human Services Selectively cytotoxic IL-4-PE40 fusion protein
US6051405A (en) * 1986-09-24 2000-04-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Constructs encoding recombinant antibody-toxin fusion proteins
US4892827A (en) * 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
US5206353A (en) * 1988-07-23 1993-04-27 The United States Of America As Represented By The Department Of Health And Human Services CD-4/cytotoxic gene fusions
CA1340530C (en) * 1989-04-28 1999-05-04 Kok Kheong Lee Synthetic pseudomonas aeruginosa pilin peptide and related vaccines and diagnostics
US5980896A (en) * 1989-06-30 1999-11-09 Bristol-Myers Squibb Company Antibodies reactive with human carcinomas
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
AU657087B2 (en) * 1989-12-22 1995-03-02 Seragen Incorporated Hybrid molecules having translocation region and cell-binding region
US5458878A (en) * 1990-01-02 1995-10-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity
JP2665827B2 (ja) * 1990-05-11 1997-10-22 アメリカ合衆国 低―動物毒性と高殺細胞活性の改良シュードモナス外毒素
US5608039A (en) * 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
US6099842A (en) * 1990-12-03 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin
US5328984A (en) * 1991-03-04 1994-07-12 The United States As Represented By The Department Of Health & Human Services Recombinant chimeric proteins deliverable across cellular membranes into cytosol of target cells
US5190873A (en) * 1991-06-21 1993-03-02 California Institute Of Biological Research Hybrid tryptophan aporepressor containing ligand binding sites
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US5935580A (en) * 1992-04-21 1999-08-10 Institut Pasteur Recombinant mutants for inducing specific immune responses
CA2136724A1 (en) * 1992-06-18 1993-12-23 Ira H. Pastan Recombinant pseudomonas exotoxin with increased activity
US6303120B1 (en) * 1994-03-15 2001-10-16 Memorial Sloan-Kettering Institute For Cancer Research Synthesis of glycoconjugates of the lewis y epitope and uses thereof
US5635599A (en) * 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
DK0759944T3 (da) 1994-05-13 2001-11-26 Biovation Ltd Forbedringer af og relateret til peptidfremføring
US5573916A (en) * 1994-05-19 1996-11-12 Coretech, Inc. Immunogenic constructs comprising b-cell and t-cell epitopes on common carrier
DE69521331T2 (de) * 1994-11-01 2001-09-20 Winfried Wels Nukleinsäure-einbringungssystem
US5843882A (en) * 1995-04-27 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides
US5980895A (en) * 1995-10-13 1999-11-09 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin containing a disulfide-stabilized antibody fragment joined to a Pseudomonas exotoxin that does not require proteolytic activation
IL116559A (en) * 1995-11-17 2005-11-20 Yissum Res Dev Co Chimeric protein consisting of a bacterial toxin and a myelin basic protein sequence
WO1997025068A2 (en) * 1996-01-05 1997-07-17 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Mesothelin antigen and methods and kits for targeting it
US6426075B1 (en) * 1996-11-06 2002-07-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Protease-activatable pseudomonas exotoxin A-like proproteins
US6086900A (en) * 1997-03-26 2000-07-11 Board Of Regents, The University Of Texas Systems Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes
US20030054012A1 (en) * 2000-05-12 2003-03-20 Fitzgerald David J. Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
US6140066A (en) * 1998-03-24 2000-10-31 Lorberboum-Galski; Haya Methods of cancer diagnosis using a chimeric toxin
US6090388A (en) * 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
EP1242122B1 (en) * 1999-10-22 2009-09-30 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Delivery of proteins across polar epithelial cell layers
EP1224290B1 (en) * 1999-10-22 2006-06-28 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Disulfide conjugated cell toxins and methods of making and using them
US6783761B2 (en) * 2000-05-05 2004-08-31 Aphton Corporation Chimeric peptide immunogens
DK1379550T3 (da) * 2000-12-21 2009-07-06 Us Gov Health & Human Serv Et kimært protein omfattende non-toxisk pseudomonas exotoxin A og en type IV pilin sekvenser
EP1549144A4 (en) * 2002-10-04 2010-01-06 Univ California METHOD FOR THE TREATMENT OF CANCER BY INHIBITION OF THE WNT SIGNALING LINE
WO2004033657A2 (en) * 2002-10-07 2004-04-22 Antigenics, Inc. Heat shock protein binding fragments of cd91, and uses thereof
US7335361B2 (en) * 2003-06-09 2008-02-26 Animal Technology Institute Taiwan Fusion antigen used as vaccine
WO2006041906A2 (en) * 2004-10-04 2006-04-20 Trinity Biosystems, Inc. Methods and compositions for immunizing against pseudomonas infection
US8877714B2 (en) * 2005-06-14 2014-11-04 Raptor Pharmaceutical Inc. Compositions comprising receptor-associated protein (RAP) variants specific for LRP2 and uses thereof
WO2008118013A2 (en) * 2007-03-23 2008-10-02 To-Bbb Holding B.V. Targeted intracellular delivery of antiviral agents
US20100143920A1 (en) * 2007-04-06 2010-06-10 The Trustees Of The University Of Pennsylvania Surfactant Protein D is a Biomarker for Steroid Responsiveness in Asthma and Chronic Obstructive Pulmonary Disease

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006025782A (ja) * 2004-07-21 2006-02-02 Healthbanks Biotech Co Ltd スーパー抗原融合蛋白及びその応用方法
JP2011510988A (ja) * 2008-01-31 2011-04-07 ヘルスバンクス ユーエスエー インコーポレイテッド ワクチンとしてのキメラｈｉｖ融合タンパク質

Also Published As

Publication number Publication date
US8092809B2 (en) 2012-01-10
ES2249838T3 (es) 2006-04-01
EP1000163A1 (en) 2000-05-17
DK1000163T3 (da) 2006-02-06
DE69831951T2 (de) 2006-07-27
WO1999002713A1 (en) 1999-01-21
US20090269368A1 (en) 2009-10-29
EP1000163B1 (en) 2005-10-19
AU8481398A (en) 1999-02-08
AU731703B2 (en) 2001-04-05
CA2295971A1 (en) 1999-01-21
CA2295971C (en) 2011-02-08
ATE307208T1 (de) 2005-11-15
DE69831951D1 (de) 2006-03-02
JP2009079068A (ja) 2009-04-16

Similar Documents

Publication Publication Date Title
US8092809B2 (en) Pseudomonas exotoxin A-like chimeric immunogens
US20090081235A1 (en) Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
US7314632B1 (en) Pseudomonas exotoxin A-like chimeric immunogens
US8309102B2 (en) Methods and compositions for immunizing against Chlamydia infection
AU732809B2 (en) Compositions and methods for treating viral infections
US20090285848A1 (en) Methods and compositions for immunizing against pseudomonas infection
WO2004083251A2 (en) Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
KR20020084841A (ko) Ｉｌ5 활성을 다운-조절하는 방법
EP1000162B1 (en) $i(PSEUDOMONAS) EXOTOXIN A-LIKE CHIMERIC IMMUNOGENS FOR ELICITING A SECRETORY IGA-MEDIATED IMMUNE RESPONSE
MÉVÉLEC et al. Mapping of B epitopes in GRA4, a dense granule antigen of Toxoplasma gondii and protection studies using recombinant proteins administered by the oral route.
US8961987B2 (en) Immunogen comprising the HIV GP120 V3 loop in a conformation that induces broadly neutralizing antibodies
EP1696033A2 (en) Pseudomonas exotoxin A-like chimeric immunogens
WO1992017590A1 (en) Therapeutic and preventive vaccines for hiv
AU2006200454B2 (en) Compositions and methods for treating viral infections
JP2003533542A (ja) Ｔ細胞結合リガンド、それを含むペプチド構築物およびそれらの免疫障害を処置するための使用
AU2004201321A1 (en) Compositions and methods for treating viral infections
AU2006200455A1 (en) Compositions and methods for treating viral infections

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050706

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050706

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080612

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080903

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20081211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091015

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100115

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100212

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100305